20.71
-0.62 (-2.91%)
| Penutupan Terdahulu | 21.33 |
| Buka | 21.42 |
| Jumlah Dagangan | 1,706,483 |
| Purata Dagangan (3B) | 1,993,957 |
| Modal Pasaran | 2,863,323,136 |
| Harga / Pendapatan (P/E Ke hadapan) | 111.11 |
| Harga / Jualan (P/S) | 9.91 |
| Harga / Buku (P/B) | 17.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 |
| Margin Keuntungan | -26.41% |
| Margin Operasi (TTM) | 70.24% |
| EPS Cair (TTM) | -1.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -29.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 108.23% |
| Nisbah Semasa (MRQ) | 5.15 |
| Aliran Tunai Operasi (OCF TTM) | 61.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.46 M |
| Pulangan Atas Aset (ROA TTM) | -5.86% |
| Pulangan Atas Ekuiti (ROE TTM) | -26.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arrowhead Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.88 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.02% |
| % Dimiliki oleh Institusi | 77.19% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 85.00 (HC Wainwright & Co., 310.43%) | Beli |
| Median | 60.00 (189.72%) | |
| Rendah | 48.00 (Morgan Stanley, 131.77%) | Pegang |
| 48.00 (Goldman Sachs, 131.77%) | Pegang | |
| Purata | 60.71 (193.14%) | |
| Jumlah | 5 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 49.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Dec 2025 | 85.00 (310.43%) | Beli | 57.95 |
| 08 Oct 2025 | 80.00 (286.29%) | Beli | 36.94 | |
| B of A Securities | 01 Dec 2025 | 62.00 (199.37%) | Beli | 56.25 |
| Chardan Capital | 01 Dec 2025 | 60.00 (189.72%) | Beli | 56.25 |
| 19 Nov 2025 | 60.00 (189.72%) | Beli | 38.97 | |
| Morgan Stanley | 26 Nov 2025 | 48.00 (131.77%) | Pegang | 57.71 |
| 12 Nov 2025 | 45.00 (117.29%) | Pegang | 41.42 | |
| Goldman Sachs | 20 Nov 2025 | 48.00 (131.77%) | Pegang | 38.09 |
| Piper Sandler | 19 Nov 2025 | 70.00 (238.00%) | Beli | 38.97 |
| RBC Capital | 19 Nov 2025 | 52.00 (151.09%) | Beli | 38.97 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |